Moderna Inc. (NASDAQ:MRNA) faces challenges as part of ongoing clinical trials for its novel Coronavirus vaccine.The company’s contractors are struggling to enroll trial participants from minority groups, highly needed to test the vaccine's efficacy.
COVID-19 Trials
The drugmaker has since had to slow down its late-stage trial enrollment as it tries to get enough Latino's, Native American volunteers, and Blacks to take part in the trials. The company has also had to seek help from academic researchers from minority groups in order to get the right number of people to assist in the trials.
Moderna was planning to enroll up to 30,000 people into the trials. As of the start of October, only 33% of the enrolled participants were from minority groups. The company needs participants from minority groups, given that the rate of coronavirus infection is much higher in such groups. In August, for instance, black individuals contracted the virus two times higher than whites. In addition, five times more blacks are hospitalized compared to whites.
Communities of color account for the biggest percentage of healthcare workers and population and at a higher risk for COVID-19 complications. Moderna cannot prove its coronavirus vaccine's efficacy without adequately testing it on this subset of the population.
COVID-19 Trials Funding
In addition, increased trial participation would go a long way in addressing distrust between communities of color and the larger medical industry. In the recent past, there has been an outrage over minorities’ underrepresentation in crucial pharmaceutical research.
Moderna is among a list of other U.S drug makers that are in the race against time to come up with a vaccine that will help put to rest the long-running coronavirus pandemic. The pandemic has already claimed more than 1 million lives worldwide, with the U.S leading with more than 210,000 deaths.
The U.S drugmaker has already received more than $1 billion in government funding to accelerate the much-needed vaccine development. It has also received an additional $1.5 billion to supply the American public should the vaccine succeed in clinical trials.